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CHAPTER I 
INTRODUCTION 
Oral administration of drugs has been practiced for centuries and, most recently, 
through tablets and capsules. Injectables came into being approximately 130 years ago, 
but have only become acceptable since the development of a better understanding of 
sterilization [1]. Topical application has also been used for centuries, predominantly in the 
treatment of localized skin diseases. Oral delivery is by far the easiest and most 
convenient way of delivering drugs especially when repeated and routine administration is 
required. Therefore, to achieve as well as to maintain the drug concentration within 
therapeutically effective range needed for treatment, it is often necessary to take this type 
of drug delivery system several times a day. This results in significant fluctuations in 
plasma drug concentration levels leading to marked side effects in some cases. 
The next era of health care will demand more accommodating delivery systems for 
sensitive drug classes. Patient compliant, noninvasive and sustained delivery will become 
the key feature desirable of any drug delivery system. 
Modified release drug delivery system can be divided into four categories [2]. 
a) Delayed release. 
b) Sustained release. 
i. Controlled release. 
ii. Extended release. 
c) Site specific targeting. 
d) Receptor targeting. 
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a) Delayed release: 
These systems are those that use repetitive, intermittent dosing of a drug from one  
or more immediate release units incorporated into a single dosage form. Examples of 
delayed release systems include repeat action tablets and capsules and enteric coated 
tablets where timed release is achieved by a barrier coating.  
 
b) Sustained release: 
The term “sustained release” describes a pharmaceutical dosage form formulated 
to retard the release of a therapeutic agent such that its appearance in the systemic 
circulation is delayed and/ or prolonged .The onset of its pharmacologic action is often 
delayed and the duration of its therapeutic effect is sustained.   
 
i) Controlled release: 
The term “controlled release” implies the release of drug ingredient(s) from 
controlled-release  drug delivery system proceeds at a rate profile that is not only 
predictable kinetically, but also reproducible from one unit to another.  
 
ii)    Extended release: 
 Pharmaceutical dosage forms that release the drug slower than normal manner at 
predetermined rate and necessarily reduce the dosage frequency by two folds. 
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c) Site specific targeting: 
These systems refer to targeting of a drug directly to a certain biological location. In 
this case the target is adjacent to or in the diseased organ or tissue. 
   
d) Receptor targeting: 
These systems refer to targeting of a drug directly to a certain biological location. In 
this case the target is the particular receptor for a drug within an organ or tissue. Site 
specific targeting and receptor targeting systems satisfy the aspect of drug delivery and are 
also considered to be controlled drug delivery systems. 
 
Controlled drug delivery systems: 
 In the mid- to late 1960s, the term “controlled drug delivery” came into being to 
describe new concepts of dosage-form design. These concepts usually involved 
controlling drug dissolution, but also had additional objectives. The primary objectives of 
a controlled-release system have been to enhance safety and extend duration of action. 
Today, we also have controlled-release systems designed to produce more reliable 
absorption and to improve bioavailability and efficiency of delivery. 
 
Controlled drug delivery systems hold the major credibility because of its obvious 
advantages of [3], 
a) Increase in patient compliance. 
b) Reduction in total dose administered, thereby, 
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• Minimize or eliminate local and systemic side effects. 
• Minimize drug accumulation with chronic use. 
• Obtain less potentiation or reduction in drug activity with chronic use. 
c) Improve efficiency in treatment. 
• Cure or control condition more promptly. 
• Reduces fluctuation in plasma drug concentration. 
• Improve bioavailability of some drugs.  
• Possibly reduced patient care time. 
• Improved patient compliance. 
 
Some of the disadvantages of controlled drug delivery systems are as follows, 
• Longer time to achieve therapeutic blood concentrations. 
• Dose dumping. 
• Sustained concentration decline in overdose cases. 
• Lack of dosage flexibility. 
• Usually, greater expense. 
• Enhanced first pass effect. 
 
Various forms of controlled drug delivery systems are [4] 
¾ Oral drug delivery systems. 
¾ Mucosal drug delivery systems. 
¾ Nasal drug delivery systems. 
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¾ Ocular drug delivery systems. 
¾ Transdermal drug delivery systems. 
¾ Parenteral drug delivery systems. 
¾ Vaginal drug delivery systems. 
¾ Intrauterine drug delivery systems. 
¾ Systemic delivery of peptide based pharmaceuticals. 
  
Innovations in the area of drug delivery are taking place at a much faster as 
compared to last two decades. Improved patient compliance and effectiveness are 
inextricable aspects of a new drug delivery system [5]. A large contribution to these novel 
systems appeared as modifications of the active drug or use of formulation excipients to 
modulate drug pharmacokinetics, safety, efficacy and metabolism. A more radical 
approach has been to explore newer interfaces on the body for introducing therapeutics. 
One such approach, transdermal drug delivery, makes use of human skin as a port of entry 
for systemic delivery of drug molecules.  
 
Transdermal drug delivery systems: 
 Transdermal delivery systems are specifically designed to obtain systemic blood 
levels and have been used in the U.S. since the 1950s. Transdermal permeation, or 
percutaneous absorption, can be defined as the passage of a substance, such as a drug, 
from the outside of the skin through its various layers into the bloodstream. 
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 The first commercially available prescription patch was approved by the U.S.Food 
and Drug Administration in December 1979 [6], which administered scopolamine for 
motion sickness. 
 There are now more than 35 transdermal products, containing atleast 13 approved 
molecules. According to a report by Jain PharmaBiotech, the value of the global market 
for transdermal delivery was $12.7 billion in the year 2005 and is expected to increase to 
$21.5 billion in the year 2010 and $31.5 billion in the year 2015 [7] . Nowadays, the 
transdermal route has become one of the most successful and innovative focus for research 
in drug delivery, with around 40% of the drug candidate being under clinical evaluation 
related to transdermal or dermal systems [8]. 
Factors limiting the success of transdermal technology include local skin irritation 
and other adverse reactions associated with certain drugs and formulation, limitation on 
the dose of drug that can be delivered transdermally, a lag time associated with the 
delivery of the drug across the skin, resulting in a delay in onset of action, variation of 
absorption rate based on site of application, skin disease, and variation in adhesive 
effectiveness in different individuals. 
 Over the last 25 years, the transdermal patch has become a proven technology 
accepted as offering a variety of significant clinical benefits over other dosage forms. 
Drug delivery direct to the systemic circulation via the application to the skin appears to 
be a desirable alternative to oral delivery for several good reasons [9]: 
• Improved patient compliance. 
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• Patients have difficulty in swallowing tablets and capsules and some patients are 
tempted to crush tablets to assist in swallowing which destroys any controlled release 
characteristics of the tablets. 
• Many orally delivered drugs irritate the gastrointestinal mucosa and a large number 
undergo extensive ‘first-pass’ inactivation by the liver. 
• A controlled delivery of drugs through the skin can provide less fluctuation in the 
circulating drug levels. 
• Greater flexibility of dosage in that dosing can be easily terminated by removal of the 
TDDS. 
 
The non-invasive character of TDDS makes it accessible to a wide range of patient 
populations and a highly acceptable option for drug dosing. 
 
 
 
 
   
 
 
 
 
. 
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CHAPTER II 
TRANSDERMAL DRUG DELIVERY SYSTEM – A REVIEW. 
“Transdermal drug delivery system is a non invasive, self-contained, discrete dosage 
forms which, when applied to the intact skin, deliver the drug(s), through the skin, at a 
controlled rate to the systemic circulation”. 
Recently, the transdermal route has vied with oral treatment as the most successful 
innovative research area in drug delivery. In the USA, out of 129 drug delivery candidate 
products under clinical evaluation, 51 are transdermal or dermal systems; 30% of 77 
candidate products in preclinical development represent such drug delivery. The worldwide 
transdermal market approaches £2 billion, yet is based on only ten drugs — scopolamine 
(hyoscine), nitroglycerine, clonidine, estradiol (with and without norethisterone or 
levonorgestrel), testosterone, fentanyl and nicotine, with a lidocaine patch soon to be 
marketed. 
 
Advantages of Transdermal Drug Delivery System (TDDS): 
• Prolonged therapy and continuous drug delivery is possible with once daily or 
multiday patches.  
• Enables utilization of drugs with short-half-life and low therapeutic index due to 
sustained therapeutic effect of transdermal drug delivery system and Provides more 
consistent treatment of chronic disease. 
• Facilitates more predictable drug absorption due to avoidance of GI tract variables 
(pH, motility, transit time, presence of food) 
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• Avoidance of “Hepatic first pass effect” and reduction of dose for some drugs. 
• Provides an alternative route when oral dosing is unsuitable. 
• Minimizes fluctuations in plasma drug concentration through controlled drug input, 
thereby abatement of side effects.            
• Noninvasive, More convenient, Painless, Lower risk of complications and Suitable 
for outpatient use. 
• Reduces dosing frequency and improves patient compliance. 
• Removed easily and cessation of drug input in case of toxicity. 
 
Limitations of Transdermal Drug Delivery System: 
• Drug candidates with molecular weight more than 500 daltons fail to penetrate 
stratum corneum. 
• Drugs with very low or high partition coefficient are non-conducive for transdermal 
drug delivery system. 
• Drugs with high melting point fail to cross stratum corneum due to their low 
solubility in both water and fat. 
• Drugs that require high blood levels cannot be administered. 
• Adhesives used may not adhere well to all types of skin. 
• Drugs or ingredients used in formulation may cause skin irritation (or) sensitization. 
• Transdermal drug delivery systems may not be economical to some patients. 
 
Skin – An effective barrier for permeation: 
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The skin is one of the most extensive and readily accessible organs of the human 
body. It receives about one-third of the blood circulation through the body. The skin is a very 
effective barrier for the permeation of most xenobiotics. Only a very little drug actually 
arrives at the site action. 
 Skin is a multilayered tissue consisting of Epidermis, Dermis and Hypodermis. 
 Stratum corneum (or) horny layer is the outermost layer of epidermis, which restricts 
the inward and outward movement of chemical substances. These are compacted, flattened, 
dehydrated and keratinized cells which are physiologically inactive. 
Figure - 1 
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Stratum corneum has two distinct chemical regions,  
i) The mass of intracellular protein  
ii) The intercellular lipoidal medium. 
The epidermis rests on the much thicker (2000 µm) dermis. The dermis essentially 
consists of about 80% protein in a matrix of mucopolysaccharide ground substance. Also 
contained within the dermis are lymphatics, nerves and epidermal appendages such as hair 
follicles, sebaceous glands and sweat glands. 
 
Pathways involved in drug permeation: 
Percutaneous absorption (or) permeation involves passage of drug (or) chemicals 
through the epidermis itself (Transepidermal absorption) or diffusion through shunts offered 
by relatively widely distributed hair follicles and eccrine glands (transappendegeal).  
    Figure - 2  
 
 
Transepidermal (or Transcorneal) penetration includes intracellular and intercellular 
penetration, hydrophilic drugs generally seen to permeate through intracellular pathway. As 
stratum corneum hydrates, water accumulates near the outer surface of the protein filaments. 
Polar molecules appear to pass through this immobilized water. Non polar substances 
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permeate through intercellular penetration. These molecules diffuse into the non-aqueous 
lipid matrix imbibed between the protein filaments. 
In Transappendegeal permeation (shunt pathway) the drug molecule may transverse 
through the hair follicles, the sebaceous pathway of pilosebaceous apparatus or the aqueous 
pathway of the salty sweat glands.           
The transdermal permeation can be visualized as composite of a series in sequence as: 
1. Adsorption of a penetrant molecule onto the surface layers of stratum corneum. 
2. Diffusion through stratum corneum and through viable epidermis. 
3.   Finally through the papillary dermis into the microcirculation. 
The viable tissue layer and the capillaries are relatively permeable and the peripheral 
circulation is sufficiently rapid. Hence diffusion through the stratum corneum is the rate 
limiting step. 
Basic components of TDDS: 
¾ Polymer matrix / Drug reservoir. 
¾ Drug. 
¾ Permeation enhancers.  
¾ Adhesives. 
¾ Backing laminates. 
¾ Release liner. 
¾ Other excipients like plasticizers and solvents. 
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Polymer matrix / Drug reservoir: 
Polymers are the backbone of TDDS, which control the release of the drug from the 
device. Polymer matrix can be prepared by dispersion of drug in liquid or solid state 
synthetic polymer base. Polymers used in TDDS should have biocompatibility and chemical 
compatibility with the drug and other components of the system such as penetration 
enhancers and PSAs. Additionally they should provide consistent and effective delivery of a 
drug throughout the product’s shelf life and should be of safe.  
The following criteria should be satisfied for a polymer to be used in transdermal 
formulations, 
• Molecular weight, glass transition temperature and chemical functionality of the 
polymer should be such that the specific drug diffuses properly and gets released 
through it. 
• It should be stable, non reactive with drug, easily manufactured and fabricated into 
the desired product and inexpensive. 
• The polymer and its degradation product must be non toxic to the host. 
• The mechanical properties of the polymer should not deteriorate excessively when 
large amount of active agent are incorporated. 
 
The polymers utilized for TDDS can be classified as:   
• Natural Polymers: e.g. cellulose derivatives, zein, gelatin, shellac, waxes, gums, 
natural rubber and chitosan etc. 
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• Synthetic Elastomers: e.g.polybutadiene, hydrin rubber, polyisobutylene, 
silicon rubber, nitrile, acrylonitrile, neoprene, butylrubber etc. 
• Synthetic Polymers: e.g. polyvinyl alcohol, polyvinylchloride, polyethylene, 
polypropylene, polyacrylate, polyamide, polyurea, polyvinylpyrrolidone, 
polymethylmethacrylate etc. 
The polymers like cross linked polyethylene glycol, eudragits, ethyl cellulose, 
polyvinylpyrrolidone and hydroxypropylmethylcellulose are used as matrix formers for 
TDDS. Other polymers like EVA, silicon rubber and polyurethane are used as rate 
controlling membrane.  
Drug:  
The transdermal route is an extremely attractive option for the drugs with appropriate 
pharmacology and physical chemistry. Transdermal patches offer more benefits to drugs 
which undergo extensive first pass metabolism, drugs with narrow therapeutic window, or 
drugs with short half life which causes non- compliance due to frequent dosing.  
Drug selection for TDDS: 
 The ideal characteristics for a drug candidate to be formulated as Transdermal 
formulation are as follows      
 
Parameters Ideal characteristics 
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Aqueous solubility. 
Lipophilicity 
Molecular weight. 
Melting point. 
PH of aqueous saturated solution. 
Dose deliverable 
>1mg/ml 
10<Kw/o<1000 
<500 daltons 
<200oc 
5 to 9 
<10mg/day. 
 
Permeation Enhancers: 
These are the chemical compounds that increase permeability of stratum corneum so 
as to attain higher therapeutic levels of the drug candidate. Penetration enhancers interact 
with structural components of stratum corneum viz proteins or lipids. They alter the protein 
and lipid packaging of stratum corneum, thus chemically modifying the barrier functions 
leading to increased permeability. 
Types of permeation 
enhancers 
Mechanism of permeation Examples 
Solvents 
 
 
 
 
 
Surfactants 
 
 
 
By swelling of polar pathway. 
By fluidizing lipids. 
 
 
 
 
By enhancing the polar pathway 
By irritating the skin. 
Methanol, ethanol, Alkyl 
methyl sulfoxides – 
dimethylsulfoxide, 
pyrrolidones, 
miscellaneous solvents – 
propylene glycol etc. 
 
Anionic surfactants – 
Dioctylsulphosuccinate, 
Sodium lauryl sulphate, 
Decodecylmethyl 
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Bile salts 
 
 
 
Binary systems 
 
 
 
Miscellaneous chemicals 
 
 
 
 
 
 
 
 
 
By opening up the heterogeneous 
multilaminate pathway. 
sulphoxide etc.      
Nonionic surfactants – 
Pluronic F127, Pluronic 
F68, 
 
Sodium taurocholate, 
Sodium deoxycholate, 
Sodium tauroglycocholate. 
 
Propylene glycol – oleic 
acid and 1, 4-butane diol-
linoleic acid.   
 
Urea, N,N-dimethyl-m-
toluamide, Eucalyptol, 
soya bean casein. 
Adhesives: 
 The fastening of all transdermal devices to the skin has so far been done by using a 
pressure sensitive adhesive. The pressure sensitive adhesive can be positioned on the face of 
the device or in the back of the device and extending peripherally. Both the adhesive systems 
should fulfill the following criteria 
• Should not irritate or sensitize the skin. 
• Should adhere to the skin aggressively. 
• Should be easily removed. 
• Should not leave an unwashable residue on the skin. 
• Should have an excellent contact with the skin at macroscopic and microscopic level. 
Some widely used pressure sensitive adhesives include polyisobutylenes, acrylics and 
silicones. 
Backing Laminate: 
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 Backing membranes are flexible and they provide a good bond to the drug reservoir, 
prevent drug from leaving the dosage form through the top and accept printing. The most 
comfortable backing will be the one that exhibits lowest modulus or high flexibility, good 
oxygen transmission and a high moisture vapor transmission rate. It is an impermeable 
substance that protects the product during use on the skin e.g. metallic plastic laminate, 
plastic backing with absorbent pad and occlusive base plate (aluminium foil), adhesive foam 
pad (flexible polyurethane) with occlusive base plate (aluminium foil disc) etc. 
 
Release Liner: 
During storage the patch is covered by a protective liner that is removed and 
discharged immediately before the application of the patch to skin. It is therefore regarded as 
a part of the primary packaging material rather than a part of dosage form for delivering the 
drug. However, as the liner is in intimate contact with the delivery system, it should comply 
with specific requirements regarding chemical inertness and permeation to the drug, 
penetration enhancer and water. Typically, release liner is composed of a base layer which 
may be non-occlusive (e.g. paper fabric) or occlusive (e.g. polyethylene, polyvinylchloride) 
and a release coating layer made up of silicon or teflon. Other materials used for TDDS 
release liner include polyester foil and metalized laminates.  
Other excipients:  
Various solvents such as chloroform, methanol, acetone, isopropanol and 
dichloromethane are used to prepare drug reservoir. In addition plasticizers such as 
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dibutylpthalate, triethylcitrate, polyethylene glycol and propylene glycol are added to provide 
plasticity to the transdermal patch.  
Methods of preparation: 
Mercury casting method: 
In this method mercury is taken in a Petri dish of appropriate size, in which drug 
containing polymer solution is poured into the dish over the mercury. A funnel is placed in 
an inverted position over the mercury plate and it is left over night and then the film is 
separated. 
Moulding method: 
In this homogeneous drug containing polymer solution is poured in mould of 
appropriate size and volume and it is left overnight and the film is separated. 
Preparation of different types of Transdermal patches: 
The systems that have been introduced in market can be classified into following 
types: 
¾ Matrix type  
¾ Reservoir type  
¾ Micro reservoir type  
¾ Drug in adhesive type 
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Matrix type Transdermal Patch(s): 
Drug reservoir is prepared by dissolving the drug and polymer in a common solvent. 
The insoluble drug should be homogenously dispersed in hydrophilic or lipophillic polymer. 
The required quantity of plasticizer like dibutylpthalate, triethylcitrate, polyethylene glycol or 
propylene glycol and permeation enhancer is then added and mixed properly. The medicated 
polymer formed is then molded into rings with defined surface area and controlled thickness 
over the mercury on horizontal surface followed by solvent evaporation at an elevated 
temperature. 
 The film formed is then separated from the rings, which is then mounted onto an 
occlusive base plate in a compartment fabricated from a drug impermeable backing. 
Adhesive polymer is then spread along the circumference of the film. 
Figure - 3  
 
The dispersion of drug particles in the polymer matrix can be accomplished by either 
homogenously mixing the finely ground drug particles with a liquid polymer or a highly 
viscous base polymer followed by cross linking of polymer chains or homogenously blending 
drug solids with a rubbery polymer at an elevated temperature. This system is exemplified by 
development of Nitro-Dur.  
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 Reservoir Type Transdermal Patch(s): 
The drug reservoir is made of a homogenous dispersion of drug  particles suspended 
in an unleachable viscous liquid medium (e.g. silicon fluids) to form a paste like suspension 
or gel or a clear solution of drug in a releasable solvent (e.g. ethanol). The drug reservoir 
formed is sandwiched between a rate controlling membrane and backing laminate. 
 
 
Figure - 4 
 
The rate controlling membrane can be nonporous so that the drug is released by 
diffusing directly through the material, or the material may contain fluid filled micropores in 
which case the drug may additionally diffuse through the fluid, thus filling the pores. In the 
case of nonporous membrane, the rate of passage of drug molecules depends on the solubility 
of the drug in the membrane and the thickness of membrane. Hence, the choice of membrane 
material is dependent on the type of drug being used. By varying the composition and 
thickness of the membrane, the dosage rate per unit area of the device can be controlled. 
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Rate controlling membrane may be prepared by solvent evaporation method or 
compression method. Examples of marketed preparations are Duragesic, Estradem and 
Androderm. 
Micro reservoir type transdermal patch(s): 
The drug reservoir is formed by suspending the drug solids in an aqueous solution of 
water miscible drug solubilizer e.g. polyethylene glycol. The drug suspension is 
homogenously dispersed by a high shear mechanical force in lipophillic polymer, forming 
thousands of unleachable microscopic drug reservoirs (micro reservoirs). The dispersion is 
quickly stabilized by immediately cross linking the polymer chains in-situ which produces a 
medicated polymer disc of a specific area and fixed thickness. Occlusive base plate mounted 
between the medicated disc and adhesive form backing prevents the loss of drug through the 
backing membrane. This system is exemplified by development of Nitrodisc.  
Figure - 5 
 
Drug in adhesive type transdermal patch(s):  
The drug and other selected excipients, if any, are directly incorporated into the 
organic solvent based pressure sensitive adhesive solution, mixed, cast as a thin film and 
dried to evaporate the solvents, leaving a dried adhesive matrix film containing the drug and 
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excipients. This drug in adhesive matrix is sandwiched between release liner and backing 
layer. Drug -in -adhesive patch may be single layer or multi layer. The multi layer system is 
different from single layer in that it adds another layer of drug-in-adhesive, usually separated 
by a membrane.  
Figure - 6 
 
Some examples of suitable pressure sensitive adhesives are polysiloxanes, 
polyacrylates and polyisobutylene. These pressure sensitive adhesives are hydrophobic in 
nature and are prepared as solutions of polymer dissolved in organic solvents. Hence, this 
type of system is preferred for hydrophobic drugs as it is to be incorporated into organic 
solvent based hydrophobic adhesive. Examples of marketed preparations of drug-in-
adhesives patches are Climara, Nicotrol and Deponit. 
Evaluation of Transdermal patches: 
Transdermal patches have been developed to improve clinical efficacy of the drug 
and to enhance patient compliance by delivering smaller amount of drug at a predetermined 
rate. This makes evaluation studies even more important in order to ensure their desired 
performance and reproducibility under the specified environmental conditions. These studies 
are predictive of transdermal dosage forms and can be classified into following types:  
• Physicochemical evaluation 
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• In vitro evaluation 
• In vivo evaluation 
Physicochemical Evaluation: 
  Various physicochemical evaluations for transdermal drug delivery systems are as 
follows. 
¾ Thickness  
¾ Uniformity of weight. 
¾ Drug content determination. 
¾ Moisture content. 
¾ Moisture uptake. 
¾ Flatness. 
¾ Folding endurance. 
¾ Tensile strength. 
¾ Water vapor transmission studies. 
¾ Adhesive studies. 
• Peel Adhesion properties 
• Tack properties. 
• Thumb tack test 
• Rolling ball test. 
• Quick stick (Peel tack) test. 
• Probe tack test. 
• Shear strength properties or creep resistance. 
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In vitro release studies: 
Drug release mechanisms and kinetics are two characteristics of the dosage forms 
which play an important role in describing the drug dissolution profile from a controlled 
release dosage forms and hence their in vivo performance. 
There are various methods available for determination of drug release rate of TDDS.  
• Paddle over disc. (USP apparatus 5) 
• The Cylinder modified USP Basket (USP apparatus 6). 
• The reciprocating disc (USP apparatus 7) 
In vitro permeation studies: 
The amount of drug available for absorption to the systemic pool is greatly dependent 
on drug released from the polymeric transdermal films. Usually permeation studies are 
performed by placing the fabricated transdermal patch with rat skin or synthetic membrane in 
between receptor and donor compartment in a vertical diffusion cell such as Franz diffusion 
cell or keshary-chien diffusion cell. 
In vivo Studies: 
In vivo evaluations are the true depiction of the drug performance. The variables which 
cannot be taken into account during in vitro studies can be fully explored during in vivo 
studies. In vivo evaluation of TDDS can be carried out using:  
¾ Animal models.  
¾ Human volunteers. 
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Current developments in Transdermal technologies: 
Several approaches have been tried to overcome the primary barrier, viz., stratum 
corneum to facilitate the passage of a drug through the skin. These approaches can be 
classified as follows. 
 
 
   
 
       
 
  
 
 
 
 
 
 
 
 
Recent advances in TDDS 
Structure 
based 
Electrically 
based 
Velocity 
based 
Others 
Microneedles. 
Macroflux.      
MTDS 
Iontophoresis. 
Ultrasound. 
Photomechanical 
waves. 
Electroporation. 
Electroosmosis 
Powder Ject. 
Needle free 
injections. 
Transfersomes. 
Medicated 
tattoos.           
Skin abrasion.  
Heat.                 
Laser radiation. 
Magnetophoresis. 
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CHAPTER III 
LITERATURE REVIEW 
1.             Raju.R.Thenge et al., developed a matrix type transdermal patches lercanidipine 
hydrochloride. The transdermal patches were prepared by solvent casting method. The 
patches were evaluated for physical appearance, Thickness, weight variation, folding 
endurance, percentage moisture content, in-vitro drug release study and ex-vivo skin 
permeation study. Ex- vivo permeation studies revealed that extent of drug release was 
higher in case of (polymers ERS 100 and HPMC) than (polymers ERS 100 and EC) [24]. 
 
2.            Satyanarayan pattnaik et al ., investigated polymer matrix Transdermal films of 
Alfuzosin Hydrochloride using statistical experimental design. Various physicochemical 
parameters of the transdermal films were evaluated. Influence of polymers on the 
cumulative amount of alfuzosin hydrochloride permeated per cm2 of human cadaver skin at 
24 h (Q24), permeation flux (J) and steady state permeability coefficient (PSS) were studied 
using experimental design. Ratio of EC and PVP was found to be the main influential factor 
for all the dependent variables studied. Drug loading dose was also found to influence the 
cumulative amount released but to a lesser extent [25]. 
 
3.           Kevin c. Garala et al ., studied about in-vitro characterization of monolithic 
matrix transdermal systems using HPMC/Eudragit S 100 polymer blends. Monolithic matrix 
transdermal systems containing tramadol HCl were prepared using various ratios of the 
polymer blends of hydroxy propyl methyl cellulose (HPMC) and Eudragit S 100 (ES) with 
triethyl citrate as a plasticizer. A 32 full factorial design was employed. Physical evaluation 
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was performed such as moisture content, moisture uptake, tensile strength, flatness and 
folding endurance. In-vitro diffusion studies were performed using cellulose acetate 
membrane (pore size 0.45 μ) in a Franz’s diffusion cell. The experimental results shows that 
the transdermal drug delivery system (TDDS) containing ES in higher proportion gives 
sustained the release of drug [26]. 
 
4.            Liang Fang et al ., prepared transdermal formulations of Indomethacin. The 
patches were prepared using MASCOS 10 (polyacrylic acid type) pressure sensitive 
adhesive was used to prepare a drug-in-adhesive type patch containing a variety of 
permeation enhancers. The results showed that the presence of IPM, oleic acid and Tween 
80 did not increase Indomethacin permeation from the transdermal patches compared with 
the transdermal patches containing azone and L-menthol (P > 0.05). 5% azone and 5% L-
menthol were the permeation enhancers of choice for the percutaneous absorption of 
Indomethacin [27]. 
 
5.            N. Udupa et al., investgated Glibenclamide Transdermal Patches for 
Physicochemical, Pharmacodynamic, and Pharmacokinetic Evaluations. matrix type 
transdermal patches containing glibenclamide were prepared using different ratios of ethyl 
cellulose (EC)/polyvinylpyrrolidone (PVP) and Eudragit RL-100 (ERL)/Eudragit RS-100 
(ERS) by solvent evaporation technique. All the prepared formulations were subjected to 
physicochemical studies (thickness, weight variation, drug content, moisture content and 
uptake, and flatness), in vitro release and in vitro permeation studies through mouse skin. 
The pharmacokinetic evaluation showed that the patches could maintain almost steady-state 
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concentration of drug within the pharmacologically effective range for prolonged period of 
time [28].            
 
6.  H.O. Ammar et al., investigated membrane mediated transdermal sytems of 
aspirin. The study comprised formulation of aspirin in different topical bases. Release 
studies revealed that hydrocarbon gel allowed highest drug release. In vitro permeation 
studies revealed high drug permeation from hydrocarbon gel. Several chemical penetration 
enhancers were monitored for augmenting the permeation from this base. Combination of 
propylene glycol and alcohol showed maximum enhancing effect [29]. 
 
7.  Yun-seek Rhee et al ., investigated  of monolithic matrix patch system containing 
Tulobuterol. The effect of functional groups in acrylic adhesive on tulobuterol uptake, 
release rate and permeation rate across rat skin were investigated. These results indicate that 
there was an interaction between secondary amino group of tulobuterol and the carboxy 
group of the acrylic poltmer therefore the drugs chemical structure and functional groups in 
pressure sensitive adhesives must be considered in order to formulate a transdermal patch 
system [30].  
 
8.  Mohd. Aqil et al., studied in-vivo characterization of monolithic matrix patches 
of Pinacidil monohydrate. The transdermal patches were prepared by solvent casting 
technique using Eudragit RL 100 and PVP K30. All the formulations were evaluated for 
physico-chemical parameters. The in - vivo studies showed a significant fall in BP with all 
formulations [31].  
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9.  Ramesh Panchagnula et al., developed reservoir type transdermal patches of 
naloxone. Ex vivo permeation studies were performed by employing porcine and rat skins. 
Further stability of the formulation was established for 3 months at accelerated stability 
conditions as per ICH guidelines. Based on ex vivo data, the surface area (SA) of the patch 
was predicted to be 39.6 cm2 in order to achieve therapeutic blood levels. Upon single dose 
administration, the steady-state levels were maintained from 4–48 h, which proves the clear 
advantage of transdermal delivery system over the current mode of administration [32]. 
 
10.  J.-C. Olivier et al., performed In vitro comparative studies of two marketed 
transdermal nicotine delivery systems: Nicopatch® and Nicorette®. Release profiles were 
obtained using the FDA paddle method, and skin permeation profiles using Franz-type 
diffusion cells. Using the first method, nicotine release followed the polymer matrix 
diffusion-controlled process, as suggested by the linear Q versus t1/2 relationship. 
Cumulative amounts released from Nicopatch were twice the amounts released from 
Nicorette, but the released fractions were almost equal for both TDS (~50%). Using 
diffusion cells, skin permeation rates were constant over the time: they were not 
significantly different between both TDS and close to in vivo claimed releases [33]. 
 
11. Soodabeh Davaran et al., developed a novel prolonged-release nicotine 
transdermal patch. An inclusion complex formed between the nicotine and ß-cyclodextrine 
(ß -CD) was used in drug depot. The usefulness of a specially cross-linked polyvinyl alcohol 
(cross-PVA) membrane was investigated as a rate controlling membrane. The influence of 
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carbopol polymers, type C-934P and C-940 and propylene glycol on transdermal permeation 
of nicotine through the rat skin was investigated. The results indicated a maximum flux of 
42 μg cm-2 h-1 after 48 h from the patches made from C-934P when the propylene glycol 
concentration was 15% and the nicotine ß-CD mole ratio in the inclusion complex was 3:1 
[34]. 
 
 
12. P. Santi et al ., developed a bioadhesive transdermal film of oxybutynin. 
Transdermal films were prepared by dissolving in water an adhesive (Plastoid®), a film-
forming polymer (polyvinyl alcohol), a plasticizer (sorbitol) and the drug. The mixture was 
then spread on siliconized paper and oven-dried.Permeation experiments were conducted in 
Franz-type diffusion cells using rabbit ear skin as barrier. Oxybutynin showed good 
permeation characteristics across the skin. When the film was applied in occlusive 
conditions the release profiles were much higher than in non-occlusive conditions, reaching 
50% of drug permeated after 24 h [35]. 
 
13. M. Aqil et al., prepared matrix type transdermal delivery of pinacidil 
monohydrate. The monolithic matrix type transdermal drug delivery systems of pinacidil 
monohydrate (PM) were prepared with Eudragit RL-100 and PVP K-30, by film casting 
technique on mercury substrate and characterised in vitro by drug release studies using 
paddle over disc assembly, skin permeation studies using Keshary and Chein diffusion cell 
on albino rat skin and drug-excipient interaction analysis [36]. 
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14. Charles M. Heard et al., investigated adhesive transdermal patch of primaquine 
with national starch. This work investigated the permeation of primaquine across full-
thickness excised human skin from two acrylate transdermal adhesives. Primaquine base 
was formulated with National Starch 387-2516 and 387-2287. The patches were applied to 
cadaver skin in Franz-type diffusion cells and the permeation of primaquine determined 
over a 24-h period. Relatively high fluxes were found. It was determined that a simple patch 
with a diameter of ~13 cm2 could deliver a therapeutic in vivo dose [37]. 
 
15. M. Guyot et al., developed matrix type propranolol adhesive patch. Propranolol 
hydrochloride, a water-soluble drug, was incorporated in three transdermal delivery systems 
using three polymers (hydroxypropylmethylcellulose, polyisobutylene and 
Ucecryl®MC808). The influence of different factors (polymeric material, matrix thickness, 
drug content, thickness of the adhesive layer and presence of a dissolution enhancer) was 
investigated. The best release modulation was obtained from Ucecryl matrices. In all 
matrices types, propylene glycol accelerated propranolol release rate [38]. 
 
16. Toshikiro Kimura et al., investigated Skin permeation of propranolol from 
polymeric film containing terpene enhancers for transdermal use. polymeric film 
formulations were prepared by employing ethyl cellulose (EC) and polyvinyl pyrrolidone 
(PVP) as a film former and dibutyl phthalate (DBP) as a plasticizer. Terpenes such as 
menthol and cineole, and propylene glycol (PG) were also employed as a chemical enhancer 
to improve the skin penetration of propranolol hydrochloride. The uniformity of drug 
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content was evidenced by the low S.D. values for each film preparation. Cineole showed 
better results when compared with menthol and propylene glycol [39]. 
 
17. Ayman El-Kattan et al., discussed the kind of skin model that will be used to 
evaluate the drug permeation; the mathematical model that will be used to characterize the 
permeation of the drug across the skin and the diffusion apparatus that will be used to 
conduct the permeation study [40]. 
 
18. Dae – duk kim et al., a reservoir-type testosterone transdermal delivery system. 
A reservoir-type transdermal delivery system of testosterone (TS) was developed using an 
ethanol/water (70:30) cosolvent system as the vehicle. The permeation studies were 
performed with keshary chien cell. The maximum permeation rate achieved by 70% (v/v) of 
ethanol was further increased from 2.69 to 47.83 μg/cm2/h with the addition of 1.0% 
dodecylamine as the skin permeation enhancer [41]. 
 
19. Charles M. Heard et al., investigated Triclosan release from transdermal 
adhesive formulations. Model patches were prepared using DuroTak® 2287, 2516 and 2051 
acrylic polymer adhesives loaded with 0, 30 and 50 mg per 0.785 cm2 triclosan and 
dissolution was measured over a 12-h period. There was no apparent difference between the 
adhesives at the 30 mg patch loading, but at 50 mg, the trend for increased release was 2051 
> 2516 > 2287 [42]. 
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20. S.S. Agrawal et al., investigated transdermal controlled administration of 
verapamil Hcl. Transdermal drug delivery (TDD) systems of Verapamil Hcl using 
hydrophilic polymers -- polyvinyl alcohol (PVA) and polyvinyl pyrrolidone (PVP) and 
different concentrations of an enhancer, d-limonene were developed. In-vitro permeation 
profiles across the guinea-pig dorsal and human cadaver skins using a Keshary-Chien 
diffusion cell are reported [43]. 
 
21. Janardhanan Bagyalakshmi et al., developed membrane moderated transdermal 
patches of ampicillin sodium. The membrane-type transdermal systems were prepared using 
a drug with various antinucleant polymers - hydroxypropyl methylcellulose (HPMC), 
methylcellulose (MC), cellulose acetate phthalate,chitosan,sodium alginate(SA), and sodium 
carboxymethylcellulose -in an ethanol: pH 4.7 buffer volatile system by the solvent 
evaporation technique with HPMC as the rate-controlling membrane for all the systems. The 
in vivo study of the ampicillin sodium patch exhibited a peak plasma concentration Cmax of 
126 μg/mL at Tmax 4 hours [44]. 
 
22. Udhumansha Ubaidulla et al., prepared monolithic matrix patches of Carvedilol 
using hydrophilic and hydrophobic polymers. Matrix-type transdermal therapeutic system 
containing carvedilol with different ratios of hydrophilic and hydrophobic polymeric 
combinations by the solvent evaporation technique. Based on physicochemical and in vitro 
skin permeation studies, patches coded as F3 (ethyl cellulose: polyvinyl pyrrolidone, 
7.5:2.5) and F6 (Eudragit RL: Eudragit RS, 8:2) were chosen for further in vivo studies. The 
bioavailability studies in rats indicated that the carvedilol transdermal patches provided 
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steady-state plasma concentrations with minimal fluctuations and improved bioavailability 
of 71% (for F3) and 62% (for F6) in comparison with oral administration [45]. 
 
23. S. Narasimha Murthy et al ., investigated Physical and Chemical Permeation 
Enhancers in Transdermal Delivery of Terbutaline Sulphate. The study was designed to 
control the release 
 of matrix type transdermal delivery systems of TS using HPMC. Because of the low 
permeability of the drug, enhancers had to be used in the formulations. The in vitro 
diffusion studies were carried out in a modified Keshary-Chien diffusion cell using distilled 
water as the receptor medium [46]. 
 
24. V.G.Jamakandi et al., investigated formulation, characterization and evaluation 
of matrix type transdermal patches of nicorandil. Different grades of HPMC were used for 
development of transdermal patches. All the prepared formulations were subjected to 
physicochemical studies (thickness, weight variation, drug content, moisture content and 
uptake, and flatness), in vitro release and in vitro permeation studies through mouse skin 
[47].  
 
25. Stanislaw Janicki et al., investigated the penetration of terpenes from matrix-
type transdermal systems through human skin. Polyurethane matrices containing up to 39% 
of the terpenes eucalyptol, L-limonene, D-limonene, dipentene or terpinolene were 
produced. Release of the terpenes directly to the acceptor fluid, as well as through isolated 
human epidermis and dermis, was studied. For all terpenes the penetration was slower in the 
presence of epidermis. Release and penetration through the epidermis and dermis were 
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fastest for dipenetene (mixture of D-limonene and L-limonene), being at least 3–4 times 
faster than for D-limonene and L-limonene [48]. 
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CHAPTER IV 
OBJECTIVE OF THE STUDY [49] 
Transdermal delivery of drugs through the skin to the systemic circulation provides a 
convenient route of administration for a variety of clinical indications. Several TDDS 
containing drugs such as clonidine, estradiol, fentanyl, nicotine, nitroglycerin, oxybutynin 
and scopoloamine are available in the United States. This mode of drug delivery is more 
beneficial for chronic disorders such as Diabetes mellitus which require long term drug 
administration to maintain therapeutic drug concentration in plasma. 
 Transport of drugs or compounds via skin is a complex phenomenon, which allows 
the passage of drugs or compounds into and across the skin.  The skin is one of the most 
extensive and readily accessible organs of the human body. It receives about one-third of the 
blood circulation through the body. Hence the skin has been explored as the port of entry of 
drugs. Innovations in the area of drug delivery are taking place at a much faster pace as 
compared to the last two decades.  
Antidiabetic drugs like sulphonylureas, Meglitinides, Biguanides and 
Thiazolidinediones are used in the treatment of Type II diabetes mellitus. Though these drugs 
are absorbed orally their bioavailability varies widely because of extensive presystemic 
metabolism.In the transdermal matrix drug delivery system the polymer matrix binds with 
the drug and controls the release of the drug from the patch.(eg : Nitrodur, Duragesic) 
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 A review by Beverley J. Thomas and Barrie C. Finnin showed that current 
transdermal drug delivery (TDD) relies primarily upon occlusive patches, and is now 
considered to be a mature technology. This method is capable of delivering drugs, the use of 
which would be limited through, for example, poor oral bioavailability, side effects 
associated with high peaks or poor compliance due to the need for frequent administration.  
 
Transdermal drug delivery has been investigated and developed in order to  
¾ Avoid hepatic first pass effect. 
¾ Minimize fluctuations in plasma drug concentration. 
¾ Improve drug bioavailability. 
¾ Reduce dosing frequency and improve patient compliance. 
 
Repaglinide, a blood glucose lowering drug of Meglitinide class is used in the 
management of Type II diabetes mellitus. It is subjected to hepatic first pass metabolism 
following oral administration with systemic bioavailability of about 56% [50]. Because of its 
short half life (1 hour), the drug has to be given frequently at 0.5 to 4 mg. The conventional 
therapy with oral pharmaceutical dosage forms may result in high fluctuations in therapeutic 
plasma drug concentration with some unwanted side effects. Hence, an attempt has been 
made to develop Transdermal patches of Repaglinide that could provide desired delivery of 
the drug at a constant and predictable rate which would be beneficial for the safe and 
effective management of Type II diabetes mellitus. 
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CHAPTER V 
PLAN OF WORK 
The work plan involves formulation and evaluation of matrix type transdermal patches of 
Repaglinide. 
Part – I 
1. Determination of λmax of Repaglinide. 
2. Preparation of standard calibration curve of repaglinide. 
Part – II 
1. Formulation of transdermal patches of repaglinide by solvent casting method. 
Part – III 
1. Evaluation of transdermal patches. 
a) Characterization of the transdermal patches. 
• Physical appearance. 
• Weight uniformity. 
• Thickness of the film.  
• Folding endurance. 
• Percentage moisture content 
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• Estimation of drug content. 
b) In-vitro drug release studies. 
 Paddle over disc method (USP apparatus 5) 
c) In-vitro permeation studies. 
 Franz diffusion cell method using rat skin membrane. 
Part – IV 
1. Surface morphological study of transdermal patch before and after in- vitro 
permeation studies using scanning electron microscopy. 
Part – V 
1. Compatibility studies of drug and polymers using Fourier transformer infrared 
spectroscopy (FTIR). 
Part – VI 
1. Stability studies of Transdermal patches of repaglinide using environmental chamber. 
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CHAPTER VI 
MATERIALS AND EQUIPMENTS 
Drugs and Chemicals 
1. Repaglinide    - Gift sample from Actavis Pharma, 
Chennai. 
2. PVP     - Gift sample from Intermed Pharma,  
Chennai. 
3. HPMC (5cps)    - Gift sample from Intermed Pharma,  
Chennai. 
4. Dibutyl phthalate   - Loba Chemie private limited. 
5. Tween 60    - CDH lab 
6. Potassium dihydrogen phosphate - CDH lab 
7. Disodium hydrogen phosphate - CDH lab 
8. Sodium chloride   - CDH lab 
9. Methanol    - Astron chemicals limited 
10. Dichloromethane   - CDH lab 
11. Chloroform    - S. D fine chemicals. 
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Equipments used 
1. Petriplate with Mercury  - Borosil 
2. Electronic weighing balance  - A & D company, Japan. 
3. Hot air oven    - Sico 
4. Vernier caliper   - Linker 
5. Dissolution apparatus   - Lab India 2000 
6. Franz diffusion cell   - Universal scientifics 
7. UV-Visible spectrophotometer - Schimadzu UV – 1700 
8. Environmental chamber  - Equipment madras pvt., ltd 
9. Scanning electron microscope - JEOL-JFC-1600. 
10. FT-IR     - Schimadzu 8400 S. 
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CHAPTER VIII 
EXCIPIENTS PROFILE [56],[57],[58] 
ETHYL CELLULOSE 
Synonyms   : Aquacoat ECD; Aqualon; E462; Ethocel; Surelease. 
Nonproprietary names : BP: Ethylcellulose, PhEur: Ethylcellulosum, USPNF:  
     Ethylcellulose 
Chemical name  : Cellulose ethyl ether 
Empirical formula  : C12H23O6 (C12H22O5)n C12H23O5 
 
Structural formula  :  
     
 
Description   : Ethylcellulose is a tasteless, free-flowing, white to light   
tan colored powder. 
 
 Functional categories  : Coating agent; flavoring fixative; tablet binder; tablet  
     filler; viscosity- increasing agent. 
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Properties   
Loss on drying  : ≤ 3.0% 
Residue on ignition  : ≤ 4.0% 
Ethoxyl groups  : 44.0–51.0% 
 
Melting point   : 1650C to 1800 C 
Solubility   : Ethylcellulose is practically insoluble in glycerin,  
     propylene glycol, and water. Ethylcellulose that  
     contains less than 46.5% of ethoxyl groups is freely  
     soluble in chloroform, methyl acetate, and  
     tetrahydrofuran, and in mixtures of aromatic  
     hydrocarbons with ethanol (95%). 
Specific gravity  :  1.12–1.15 g/cm3 
 
Nominal viscosity  : 6–10 mPa s 
 
Stablility and storage  : Ethylcellulose is a stable, slightly hygroscopic material.  
     Ethylcellulose is subject to oxidative degradation in the  
     presence of sunlight or UV light at elevated  
     temperatures. 
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HYDROXY PROPYL METHYL CELLULOSE (5 cps)  
Synonyms   : Methocel; methylcellulose propylene glycol ether;  
    methyl hydroxypropylcellulose; Metolose; Tylopur 
Nonproprietary names : BP: Hypromellose, PhEur: Hypromellosum, USP:  
    Hypromellose. 
Chemical name  : Cellulose hydroxypropyl methyl ether. 
Molecular weight  : 10,000 to 1,500,000 
 
Structural formula  :  
    
 
Description   : Hypromellose is an odorless and tasteless, white or  
     creamy white fibrous or granular powder. 
Functional categories  : Coating agent; film-former; rate-controlling polymer  
     for sustained release; stabilizing agent; suspending  
     agent; tablet binder; viscosity-increasing agent. 
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Properties   
Ash    :  1.5–3.0%, 
Loss on drying  : ≤ 5.0% 
Methoxy content  : 27.0% to 30.0% 
Hydroxypropoxy  : 4.0% to 7.5% 
Melting point   : Browns at 190–200oC; chars at 225–230oC and Glass  
     transition temperature is 170–180oC. 
Solubility   : soluble in cold water, practically insoluble in  
     chloroform, ethanol and ether, but soluble in mixtures  
     of ethanol and dichloromethane, mixtures of methanol  
     and dichloromethane, and mixtures of water and  
     alcohol. 
Specific gravity  :  1.26. 
Nominal viscosity  : 5 centipoise. (2% w/v aqueous solution) 
Stablility and storage  : HPMC is a stable material, although it is hygroscopic  
     after drying. 
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POLYVINYL PYROLLIDONE (PVP K30) 
Synonyms   : Kollidon; Plasdone; polyvidone; 1-vinyl-2- 
     pyrrolidinone polymer. 
Nonproprietary names : JP: Povidone, PhEur: Povidonum.  
Chemical name  : 1-Ethenyl-2-pyrrolidinone homopolymer 
Empirical formula  : (C6H9NO)n 
Molecular weight  : 2,500 to 3,000,000 
Structural formula  :  
     
Description   : Povidone occurs as a fine, white to creamy-white 
     colored, odorless or almost odorless, hygroscopic  
     powder. Povidones with K-values equal to or lower  
     than 30 are manufactured by spray-drying and occur as  
     spheres. Povidone K-90 and higher K-value povidones  
     are manufactured by drum drying and occur as plates. 
Functional categories  : Disintegrant; dissolution aid; suspending agent; tablet  
     binder, film forming agent, viscosity-enhancement  
     agent, lubricator and adhesive. 
 
 
 54 
 
Properties   
Water content   : ≤ 5.0%   
Residue on ignition  : ≤ 0.1% 
Vinyl pyrrolidinone  : ≤ 0.2%  
Melting point   : softens at 1500 c 
Solubility   : freely soluble in acids, chloroform, ethanol (95%),  
     ketones, methanol, and water; practically insoluble in  
     ether, hydrocarbons, and mineral oil. 
Moisture   : 3.5%   
Nominal viscosity  : 5.5–8.5 mPa s (10% w/v aqueous povidone solution)   
Stability and storage  : It is stable to a short cycle of heat exposure around    
     110 –1300C; steam sterilization of an aqueous solution  
     does not alter its properties. Povidone may be stored  
     under ordinary conditions without undergoing  
     decomposition or degradation. However, since the  
     powder is hygroscopic, it should be stored in an airtight  
     container in a cool, dry place. 
 
 
 
 
. 
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TWEEN 60 
Synonyms   : Capmul POE-S; Cremophor PS 60; Crillet 3; Drewpone  
     60K; Durfax 60 
Nonproprietary names : BP: Polysorbate 60, USPNF: Polysorbate 60, PhEur: 
     Polysorbatum 60  
Chemical name  : Polyoxyethylene 20 sorbitan monostearate. 
 
Empirical formula  : C64H126O26. 
 
Molecular weight  : 1312 
 
Structural formula  : 
     
     w +x+ y+ z = 20 (Polysorbate 60) 
    
Description   : Polysorbates have a characteristic odor and a warm,  
     somewhat bitter tasted yellow colour oily liquid  
     although it should be noted that the absolute color  
     intensity of the products may vary from batch to batch  
     and from manufacturer to manufacturer. 
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Functional categories  : Emulsifying agent; nonionic surfactant; solubilizing  
     agent; wetting, dispersing/suspending agent. 
 
 
Properties   
Flash point   :  1490c  
HLB value   : 14.9 
Stearic acid   : 40.0 to 60.0% 
Hydroxyl value  : 81 to 96.  
Solubility   : Freely soluble in ethanol and water.  
Specific gravity  : 1.1  
Surface tension.  : 42.5 (at 200c)  
Nominal viscosity  : 600 
Stability and storage  : Polysorbates are stable to electrolytes and weak acids  
     and bases; gradual saponification occurs with strong  
     acids and bases. Prolonged storage can lead to the  
     formation of peroxides. Polysorbates should be stored  
     in a well-closed container, protected from light, in a  
     cool, dry place. 
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DIBUTYL PTHALATE 
Synonyms   : Araldite 502; benzenedicarboxylic acid; benzene-o- 
     dicarboxylic acid di-n-butyl ester; butyl phthalate;  
     Celluflex DBP; Genoplast B; Hatcol DBP; Hexaplast  
     M/B; 
Nonproprietary names : BP: Dibutyl Phthalate, PhEur: Dibutylis phthalas 
Chemical name   : Dibutyl benzene-1,2-dicarboxylate 
Empirical formula  : C16H22O4 
Molecular weight  : 278.34 
Structural formula  : 
        
      
Description   : Dibutyl phthalate occurs as an odorless, oily, colorless,  
     or very slightly yellow-colored, viscous liquid. 
Functional categories  : Film-former; plasticizer; solvent. 
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Properties   
Flash point   :  1710c 
Boiling point   : 3400c   
Refractive index  : 1.491 to 1.495   
Solubility   : very soluble in acetone, benzene, ethanol (95%), and  
     ether; soluble 1 in 2500 of water at 200C. 
Relative density  : 1.043–1.048 
Dynamic viscosity  : 20 mPa s 
Stability and storage  : Dibutyl phthalate should be stored in a well-closed  
     container in a cool, dry, location. Containers may be  
     hazardous when empty since they can contain product  
     residues such as vapors and liquids. 
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CHAPTER IX 
EXPERIMENTAL DETAILS 
Preparation of standard calibration curve 
Preparation of dissolution medium [59] 
(30% v/v)Methanolic isotonic phosphate buffer pH 7.4 
  2.38 gms of disodium hydrogen phosphate, 0.19 gms of potassium dihydrogen 
ortho phosphate and 8.0 gms of sodium chloride are weighed and dissolved in 
sufficient amount of water to produce 700 ml. To this 300 ml of methanol is added to 
produce 1000ml of methanolic isotonic phosphate buffer pH 7.4. 
 100 mg Repaglinide is weighed and dissolved in a small quantity of methanol in a 
100 ml standard flask and made up to the volume with 30%v/v methanolic isotonic 
phosphate buffer (IPB) pH 7.4. From this primary stock solution 10 ml is pipetted out 
and made up to 100 ml with methanolic IPB pH 7.4 to form the secondary stock 
solution resulting in the concentration of100 µg/ml.   
 From the secondary stock solution 5ml, 10ml, 15ml, 20ml …50ml samples are 
pipetted into 100 ml volumetric standard flasks separately and made up to the volume 
with methanolic IPB pH 7.4 to get concentrations of 5 µg/ml, 10 µg/ml, 15 µg/ml, 20 
µg/ml…50 µg/ml of drug respectively. 
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λ max is found by scanning the repaglinide solution under UV-Visible 
spectrophotometer. The absorbance is measured at λ max for different concentrated 
solutions to obtain standard calibration curve. Standard calibration curve is plotted by 
taking concentration in x-axis and absorbance in y-axis. 
 The calibration curve is useful in estimation of drug content, concentration of 
drug released during in-vitro release studies and in-vitro permeation studies. 
 
Formulation of repaglinide transdermal patches  
 The solvent casting technique on mercury substrate is used to formulate the 
matrix type transdermal patches of repaglinide. Transdermal formulations of 
Repaglinide are prepared using ethyl cellulose/polyvinyl pyrrolidone (EC/PVP) and 
ethyl cellulose/hydroxyl propyl methyl cellulose (EC/HPMC) with three different total 
polymer weights like 200mg, 300mg, 400mg each having requisite ratios polymer 
mixture as shown in table 
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Table - 1 
Formulation of repaglinide loaded transdermal patches 
Sl.no Formulations 
Ingredients 
Polymer  Weight 
in mg 
Ratio Dibutyl 
phthalate 
in % 
w/w of 
polymer
s
Tween 60 
in % w/w 
of 
polymers.
1 EPA1 EC/PVP 200 4.5:0.5 30 5 
2 EPA2 EC/PVP 200 4 : 1 30 5 
3 EPA3 EC/PVP 200 3 : 2 30 5 
4 EPB1 EC/PVP 300 4.5:0.5 30 5 
5 EPB2 EC/PVP 300 4 : 1 30 5 
6 EPB3 EC/PVP 300 3 : 2 30 5 
7 EPC1 EC/PVP 400 4.5:0.5 30 5 
8 EPC2 EC/PVP 400 4 : 1 30 5 
9 EPC3 EC/PVP 400 3 : 2 30 5 
10 EHA1 EC/HPM 200 4.5:0.5 30 5 
11 EHA2 EC/HPM 200 4 : 1 30 5 
12 EHA3 EC/HPM 200 3 : 2 30 5 
13 EHB1 EC/HPM 300 4.5:0.5 30 5 
14 EHB2 EC/HPM 300 4 : 1 30 5 
15 EHB3 EC/HPM 300 3 : 2 30 5 
16 EHC1 EC/HPM 400 4.5:0.5 30 5 
17 EHC2 EC/HPM 400 4 : 1 30 5 
18 EHC3 EC/HPM 400 3 : 2 30 5 
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*The drug concentration is kept constant in all the formulations. 
*EP – Ethyl cellulose/PVP. 
*EH - Ethyl cellulose/HPMC. 
*A - 200 mg. 
*B - 300mg. 
*C - 400 mg. 
The transdermal patches are formulated such that each patch contains 1mg/cm2 
drug concentration. 
 The solvent used to dissolve EC/PVP is chloroform and for EC/HPMC the solvent 
mixture is methanol: dichloromethane (6:4) [25], 
 To the polymeric solution known weight of drug (repaglinide 25 mg) is added and 
mixed slowly with a glass rod for 30 minutes until a homogenous drug polymer 
solution is formed. Then dibutyl phthalate (plasticizer) and Tween 60 (permeation 
enhancer) of requisite quantity are added and mixed thoroughly. 
 The resulting homogenous drug-polymeric solution is poured on a mercury 
substrate (area of 25 cm2) in a petridish and dried at room temperature. The rate of 
evaporation of solvent was controlled by inverting a funnel over the petridish. The 
dried films are taken out after 24 hours and subjected for evaluation. 
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Evaluation of transdermal patches [25],[28],[47] 
a) Characterization of the transdermal patches [60] 
Physical appearance 
 All the transdermal patches are visually inspected for color, clarity, flexibility and 
smoothness. 
Weight uniformity 
 Four patches from each batch are accurately weighed using a digital balance. The 
average weight and the standard deviation values are calculated from the individual 
weights. 
Thickness of the films 
 The thicknesses of the drug loaded polymeric films are measured using a digital 
vernier caliper. The measurements are made at five different points, four at the corners 
and one at the centre of the patch. The average and standard deviation of five readings 
were calculated for each formulation. 
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Folding endurance 
Folding endurance of patches is determined by repeatedly folding the small 
strip of film at the same place till it breaks. The number of times, the film could be 
folded at the same place till it breaks will give the value of folding endurance. 
Percentage moisture content 
The prepared films are weighed individually and kept in a desiccator 
containing silica gel at room temperature for 24 hours. The films were again weighed 
and the percentage moisture content is calculated using the formula: 
Percentage moisture content = [(Initial weight – Final weight)/Final weight] x 100 
Estimation of drug content 
Transdermal patches of specified area and weight are cut into small pieces and 
are transferred into 100mL standard flask. About 5mL of methanol is added to 
dissolve the patch and then made upto 100mL with methanolic isotonic phosphate 
buffer pH 7.4. Similarly, a blank is also prepared using drug free patch. The solutions 
are filtered and the absorbance is measured at λmax (281.5) nm using UV visible 
spectrophotometer.  
b) In-vitro drug release studies [61], [62], [63] 
 The in-vitro drug release study for the transdermal patches are carried out using 
modified paddle over disc assembly USP 23, Apparatus 5. The disc apparatus consists 
of mesh screen made of stainless steel clamped in the watch glass using nylon clips. 
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The transdermal patch of area 3.14 cm2 is pasted over a small piece of aluminium foil 
(backing layer) to prevent two dimensional release. The transdermal patch with 
backing layer is placed between inert stainless steel mesh and watch glass exposing the 
patch to the medium. It is also ensured that the patch does not float inside the disc 
assembly. 
 The disc assembly containing transdermal patch is placed at the bottom of the 
dissolution vessel, with the mesh facing upwards, under the rotating paddle. The 
dissolution medium used is 900 ml of methanolic isotonic phosphate buffer pH 7.4. 
The apparatus was equilibrated to the temperature of 37 ± 0.50c operated at 50 ± 1 
rpm. The dissolution study is carried out for 12 hours. 10 ml of samples are withdrawn 
at regular intervals of 1 hour and the same volume of corresponding dissolution 
medium was replenished to maintain sink condition. 
 The amount of repaglinide released is determined by measuring the absorbance of 
the samples at 281.5 nm using UV-Visible spectrophotometer. Each test is performed 
in triplicate. 
c) In-vitro permeation studies [47], [61], [64]. 
 The in-vitro skin permeation experiments are conducted using vertical type Franz 
diffusion cells having receptor compartment capacity of 15 ml.   
Preparation of rat skin membrane  
Permeation studies are carried out after obtaining ethical committee clearance. 
Wister strains of male albino rats weighing between 180-200 gms are used for this 
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study. Membrane for the permeability studies is full thickness skin from the dorsal 
region of the rats. The hair present over the skin is removed by trimming and careful 
shaving so that the skin is not damaged. The skin is excised from rat after sacrificing. 
The subcutaneous fat present on the skin samples are removed by soaking the skin 
samples in hot water (60oc) for 45 seconds. The excised skin samples are then stored 
in frozen condition until use. 
 
Permeation studies 
 The receptor compartment is filled with 15 ml of methanolic isotonic phosphate 
buffer pH 7.4. The transdermal patches with backing membrane are firmly pressed 
onto the centre of the rat skin. Once adhesion to the skin surface had been confirmed, 
the skin is quickly mounted on the diffusion cell receptor compartment such that the 
patch was tightly secured over the flange aperture. The donor compartment is then 
placed in position and the two halves of the cell are clamped together. The whole 
assembly was placed over a magnetic stirrer. The   dissolution medium in the receptor 
compartment was stirred constantly and continuously using a magnetic bead. 
 The samples are withdrawn at regular time intervals of 1 hour and analyzed for 
drug content. Receptor phases are replenished with equal volume of dissolution 
medium at each time interval. The cumulative amounts of drug permeated per square 
centimeter of patches were plotted against time. From the graph flux (J) is determined. 
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Scanning electron microscopy [28] 
 The surface morphology of the transdermal patches before and after in-vitro skin 
permeation experiments were analyzed by scanning electron microscopy  
 
FTIR studies [28] 
 The possibility of drug - excipient interaction is investigated by FTIR. The FTIR 
graph of pure drug and physical mixture of drug – polymer are recorded.  
Stability studies [65] 
 Stability studies are performed on the formulated transdermal patches at 40 ± 2oc 
and relative humidity of 75% ± 5% maintained. The drug content of the different 
formulations are evaluated every week using UV-Visible spectrophotometer and 
physical appearance is also examined. 
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CHAPTER X 
RESULTS AND DISCUSSION 
Standard calibration curve for repaglinide 
 Known concentration of repaglinide in methanolic isotonic phosphate buffer is 
scanned to find the λmax and it was found to be 281.5 nm. Calibration curve for 
repaglinide were prepared in methanolic isotonic phosphate buffer pH 7.4 in the 
concentration range of 5 to 50µg/ml at 281.5 nm. The correlation coefficient was 
found to be 0. 0.998725148. The results are presented in the table -2. Calibration plots 
of repaglinide are shown in Fig – 7 
Formulation of repaglinide transdermal patches 
 Matrix-type transdermal patches containing repaglinide and variable combinations 
of EC/PVP and EC/HPMC were prepared as per the composition given in table - 1. 
Excellent film forming ability of these polymeric combinations were already reported 
(ref).These polymeric combinations produced smooth patches compared to patches 
prepared by a single polymer. 
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Evaluation of transdermal patches    
a) Characterization of the transdermal patches 
Physical appearance 
 All the polymers used for the formulation of transdermal patches showed good 
film forming properties. 
 The patches formed were thin, flexible, smooth and transparent. The method used 
for casting the film on a mercury substrate was found to be satisfactory.  
Weight uniformity 
 The results of weight variation tests of the patches are shown in the table-2. The 
weights of the patches ranged from 246.36 ± 1.46 mg to 482.24 ± 1.15 mg for EC/PVP 
formulations and 237.23 ± 0.64 mg to 467.02 ± 0.65 mg for EC/HPMC formulations. 
 From the results it has been found that there is less variation in weight between 
different patches of a same batch suggesting uniform distribution of drug and polymer 
over the mercury surface. 
Thickness of the patches 
 The results of thickness of the patches are shown in the table-3. The thickness of 
the patch ranged from 0.078 ± 0.007 mm to 0.148 ± 0.009 mm for formulations 
prepared with EC/PVP and 0.069 ± 0.004 mm to 0.131 ± 0.015 mm for formulations 
prepared with EC/HPMC. 
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The thickness of patches were found to increase in the following order, 
EC/PVP 200 mg – EPA1< EPA2< EPA3. 
EC/PVP 300 mg – EPB1< EPB2< EPB3. 
EC/PVP 400 mg – EPC1< EPC2< EPC3. 
EC/HPMC 200 mg – EHA1< EHA2< EHA3. 
EC/HPMC 300 mg – EHB1< EHB2< EHB3. 
EC/HPMC 400 mg – EHC1< EHC2< EHC3 
From the results it was found that thickness increases with increase in concentration of 
hydrophilic polymers (PVP and HPMC). The thickness of the patch over five different 
areas was found to be uniform, suggesting even distribution of drug and polymer over 
the mercury surface. 
Folding endurance 
 The results of folding endurance were shown in table-3. The folding endurance of 
EC/PVP patches ranged from 14.33 ± 0.471 to 27.66 ± 2.624 and that of EC/HPMC 
patches ranged from 11.66 ± 2.054 to 26.66 ± 2.054 respectively. The results from the 
table also showed that increasing concentration of hydrophilic polymers showed 
increasing folding endurance. All the patches showed good flexibility and folding 
endurance properties. 
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Percentage moisture content [25] 
 The results of moisture content studies are shown in the table-4. The moisture 
content in the formulations was found to be low and ranged from 1.68 to 2.74 for 
EC/PVP patches and 1.39 to 2.58 for EC/HPMC patches. 
 The moisture content of the transdermal patches were found to be in the following 
order,  
EC/PVP 200 mg  –  EPA1< EPA2< EPA3. 
EC/PVP 300 mg  –  EPB1< EPB2< EPB3. 
EC/PVP 400 mg  –  EPC1< EPC2< EPC3. 
EC/HPMC 200 mg  –  EHA1< EHA2< EHA3. 
EC/HPMC 300 mg  –  EHB1< EHB2< EHB3. 
EC/HPMC 400 mg  –  EHC1< EHC2< EHC3 
 It was found that the moisture content increases with increase in concentration of 
hydrophilic polymers PVP and HPMC. The presence of little moisture content helps to 
maintain the formulation stable and prevent them from becoming completely dried and 
brittle.  
Estimation of drug content 
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  The results of drug content analysis were shown in table-5. The drug content of 
the patches ranged from 96.45 ± 0.942% to 100.76 ± 1.414%. The results suggest that 
the method employed to prepare the patches shown uniformity in drug content with 
minimum variations and also the results showed that the drug has been uniformly 
distributed. 
b) In-vitro drug release studies 
 The results of in-vitro drug release studies from the transdermal patches are 
shown in the tables- 6, 7, 8, 9, 10, 11 and in figures 9, 10, 11, 12, 13 and 14 
respectively. The formulations with total polymer weight 200mg containing EC/PVP 
in the ratio (3:2) and EC/HPMC in the ratio (3:2) exhibited greatest (100.82 ± 3.78 and 
89.25 ± 1.93 respectively) percentage of drug release in 12 hours, whereas lowest 
release were observed with the formulations with total polymer weight 400 mg 
containing EC/PVP in the ratio (4.5:0.5) and EC/HPMC in the ratio (4.5:0.5) (46.14 ± 
2.47 and 46.73 ± 1.34 respectively) in 12 hours. 
Effect of hydrophilic polymers [25] [57] 
 The order of drug release from all the formulations increased in the following 
order. 
EC/PVP 200 mg – EPA1 (80.03 ± 1.369) < EPA2(91.01 ± 3.79) < EPA3 (100.82 ± 
3.78) 
EC/PVP 300 mg – EPB1(60.23 ± 1.31) < EPB2 (63.03 ± 1.32) < EPB3 (70.47 ± 
3.08). 
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EC/PVP 400 mg – EPC1 (46.14 ± 2.47) < EPC2 (52.87 ± 1.34) < EPC3 (60.30 ± 
1.20) 
EC/HPMC 200mg –EHA1 (80.79 ± 1.50) < EHA2 (82.43 ± 2.15) < EHA3(89.25 ± 
1.93) 
EC/HPMC 300mg – EHB1 (51.20 ± 1.20) < EHB2 (57.53 ± 2.34) < EHB3(62.71 ± 
1.70) 
EC/HPMC 400mg – EHC1 (46.73 ± 1.34) < EHC2(49.63 ± 1.43) < EHC3 (53.28 ± 
1.50) 
 The formulations EPA3, EPB3, EPC3 and EHA3, EHB3, EHC3 showed more 
release during initial hours due to the presence of more amount of hydrophilic 
polymers.  
From the studies it has been found that the formulations with increasing concentration 
of hydrophilic polymers like PVP and HPMC showed increase in dissolution rate 
substantially. The increase in rate of drug release is because of the ability of 
hydrophilic polymers to absorb water and hydrate the polymer matrix thereby 
promoting dissolution. The hydrophilic polymers present in the patches would leach 
out and create more pores and channels for the drug to diffuse out of the patches.  
It has also been reported that PVP act as antinucleating agent reduces the 
crystallization of the drug. Thus they play a significant role in improving the solubility 
of a drug in the matrix by sustaining the drug in an amorphous form so that it 
undergoes rapid solubilization which accounts for the increased release of the drug 
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with an increase in the PVP concentration in the patches. HPMC causes easy hydration 
and swelling of polymer matrix leading to fast release of drug [58].  
Effect of hydrophobic polymer [58] 
 The formulations EPA1, EPB1, EPC1, EHA1, EHB1 and EHC1 which contained 
more concentration of ethyl cellulose showed retarded drug release. 
The order of retardation of drug release from EC/PVP and EC/HPMC is as follows, 
EPC1(46.14±2.47) < EHC1(46.73±1.34) < EHB1(51.20±1.20) < EPB1 (60.23±1.31)  
< EPA1(80.03±1.69) < EHA1 (80.79±1.50).    
  This retarded drug release from the formulations containing higher concentration 
of ethyl cellulose may be because of hydrophobic nature of the polymer which has less 
affinity for water. This results in decrease in the thermodynamic activity of the drug in 
the patch and hence decreased drug release. The presence of ethyl cellulose a 
hydrophobic polymer controls the release of drug and maintains the integrity of the 
patch. 
 
c) In-vitro permeation studies 
Selection of formulation for permeation studies [25] [28] 
 The formulations which showed highest release (EPA3-100.82 ± 3.78% and 
EHA3 - 89.25 ± 1.93 %), lowest release (EPC1 – 46.14 ± 2.47% and EHC1- 46.73 ± 
1.34 %) and intermediate release (EPB3-70.47 ± 3.08 % and EHB3- 62.71 ± 1.70 %) 
in 12 hours were selected for in-vitro skin permeation studies in rat abdominal skin.    
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 The results of in-vitro permeation studies have been shown in the table-12, 13 and 
figures 15, 16. The formulation EPA3 with EC: PVP (3:2, 200mg – total polymer 
weight) and EHA3 with EC/HPMC showed higher permeation of 95.19% and 97.59% 
respectively in12 hours. The process of drug release was governed by diffusion and the 
polymer matrix had a strong influence on the diffusivity as the motion of a small 
molecule is restricted by the three-dimensional network of polymer chains. 
 The initial increased release of drug may be as a result of initial rapid dissolution 
of PVP (hydrophilic polymer) in the patch when it comes in contact with the hydrated 
skin, which results in accumulation of high amounts of drug on the skin surface and 
thus leads to saturation of the skin with the drug molecules. 
The steady state plasma concentration data of repaglinide is not available and in this 
event peak plasma concentration value, which is supposed to be within therapeutic 
window, may be considered as required plasma concentration for calculation of 
desired drug input rate. The mean peak plasma concentration (Cmax) of repaglinide is 
65.8ng/mL and the total clearance (ClT) is 0.633 L/h/kg. Hence, the required rate of 
drug input can be calculated as follows [25]: 
:  
Required rate of drug input  
= Required plasma concentration × Clearance = 41.673 µg/h. 
 
The results of flux achieved from the formulations are given in the table 14. From the 
results it has been found out that the formulations EPA3, EPB3, EHA3 and EHB3 with 
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flux of 68.92, 48.12, 62.66 and 51.87 µg/hr/cm2 meets the required flux but the release 
was found to be rapid, whereas the formulations EPC1and EHC1 showed a sustained 
release with a flux of 26.88 µg/hr/cm2 and 26.07 µg/hr/cm2 respectively. Hence by 
increasing the surface area of the formulations EPC1and EHC1 to 2 cm2 the required 
target flux may be achieved with sustained effect. 
 
Scanning electron microscopy 
 The results of scanning electron microscopy were shown in the figure 17, 18. The 
shows the microstructure of EC/HPMC transdermal patch before and after the drug 
permeation experiments. The films prior to in-vitro skin permeation studies showed 
uniform smooth surface. After the permeation studies the surface became rough and 
pores were formed on the surface of the patch due to diffusion of drug. The patches 
did not loose integrity after the release, further indicating that the drug was released 
from the patches predominantly through diffusion. 
FTIR studies 
 The possible drug – polymer interaction was studied by IR-spectroscopy. The 
results of IR spectroscopy were shown in the figures 19, 20, 21, 22, 23, 24. The IR 
spectral analysis of repaglinide pure drug alone showed that principal peaks were 
observed at wave numbers 3309.24, 2935.64, 1686.88, 1569.14 and 760.02. In the IR 
spectra of the physical mixture of repaglinide, EC and PVP the major peaks of 
repaglinide were 3307.84, 2934.06, 1687.64, 1567.78 and 760.68.Further in the 
physical mixture of EC, HPMC and repaglinide major peaks of repaglinide were 
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observed at 3309.62, 2934.43, 1688.97, 1568.12 and 759.33 suggesting that there is no 
interaction between the polymers and drug used in the present study. This study also 
further indicates that the polymers do not alter the performance characteristics of the 
drug from the patches. 
Stability studies 
 The formulations were subjected to stability studies for a time span of one month. 
The formulations were evaluated for physical appearance and drug content. There was 
no significant change in physical appearance and drug content. It was found that the 
formulations remained stable during the process of storage. The results are presented 
in the table 15.        
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CHAPTER XI 
SUMMARY AND CONCLUSION 
 In the present work an attempt has been made to formulate and evaluate the transdermal 
patches of repaglinide using various blends of polymer. 
 The polymeric combinations EC/PVP and EC/HPMC used for the formulation of 
transdermal patches showed good film forming property. 
 The patches formed were thin, flexible, smooth and transparent. 
 The weight variation tests showed less variation in weight and suggesting uniform 
distribution of drug and polymer over the mercury surface. 
 The thicknesses of the transdermal patches were found to increase on increasing 
concentration of hydrophilic polymers like PVP and HPMC. 
 All the patches showed good flexibility and folding endurance properties. The result 
suggests that the formulations with increased hydrophilic polymer concentration showed 
long folding endurance. 
 The moisture content in the patches were found to be low and formulations with more 
hydrophilic polymer concentrations showed more percentage moisture content. 
  The drug content analysis showed minimum variations suggesting uniform distribution 
of drug. 
 The in-vitro drug release studies showed that formulations EPA3, EPB3, EPC3, EHA3, 
EHB3 and EHC3 with increased concentration of hydrophilic polymer showed rapid 
release. 
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 Formulations EPC1 and EHC1 showed sustained release. 
 The in-vitro permeation studies showed that the required target flux is achieved with 
formulations EPC1 and EHC1 which also produces a sustained release of the drug.     
 Surface morphological studies by SEM showed the patch showed uniform smooth 
surface and did not loose integrity after release. 
 The results of compatibility studies by FTIR showed no interaction between the drug and 
polymers. 
 The result of stability studies no change in the physical appearance and drug content 
suggesting that the formulations remained stable during storage. 
It is concluded that solvent casting method using mercury substrate is useful for 
successful development of matrix type transdermal patches. The sustained release of drug 
from the transdermal patches suggests that the frequency of administration may be 
reduced. Further, the transdermal patches may improve the bioavailability of the drug by 
avoiding hepatic first pass metabolism. 
Hence we can conclude that the polymer matrix provide sustained delivery of 
drug and these systems can be used to deliver drugs with short half life and low 
therapeutic index through transdermal drug delivery systems.   
 
 
Fig - 9 Comparison of invitro release of EC/PVP patches -200 mg
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  Fig - 10 Comparison of invitro release of EC/PVP patches -300 mg
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Fig - 11 Comparison of invitro release of EC/PVP patches -400
mg
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 Fig - 12 Comparison of invitro release of EC/HPMC patches -200 mg
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Fig - 13 Comparison of invitro release of EC/HPMC patches - 300 mg
0 1 2 3 4 5 6 7 8 9 10 11 12
0
10
20
30
40
50
60
70
80
90
100
EHB1
EHB2
EHB3
Time in hours
C
u
m
u
l
a
t
i
v
e
 
p
e
r
c
e
n
t
a
g
e
 
o
f
 
d
r
u
g
 
r
e
l
e
a
s
e
d
 
 
 
 
 Fig - 14 Comparison of invitro release of EC/HPMC patches - 400 mg
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 Fig - 15 In-vitro permeation studies of EPA3, EPB3
and EPC1
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  Fig - 16 In-vitro permeation studies of EHA3, EHB3 and EHC1
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Figure - 23 
 
 
 
 
 
Figure - 24 
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Figure – 17  
SEM Photograph of Repaglinide Transdermal patch (EPC1) before permeation studies 
    
     
       
 
 
 
 
 
 
 
Figure – 18  
SEM Photograph of Repaglinide Transdermal patch (EPC1) After permeation studies. 
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